Sanofi’s emphatic exit from diabetes research comes as the field is expanding beyond a focus on glucose levels to test for cardiovascular and renal benefits – an endeavor that requires very large, very expensive clinical outcomes trials in a crowded market that leaves little room for error.
That Sanofi, a long-time diabetes stalwart, is leaving the arena is one of the most remarkable signs of the stresses...







